Single-probe Microwave Ablation (MWA) of Metastatic Liver Cancer
Not Applicable
Completed
- Conditions
- Liver Neoplasms
- Interventions
- Device: Microwave ablationDevice: Radiofrequency ablation
- Registration Number
- NCT00922181
- Lead Sponsor
- University Hospital, Gasthuisberg
- Brief Summary
Microwave ablation (MWA) is the most recent development in the field of local ablative therapies. The aim of this study was to evaluate the variability and reproducibility of single-probe MWA versus radiofrequency ablation (RFA) of metastatic liver tumours smaller than 3 cm in patients without underlying liver disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 19
Inclusion Criteria
- Unresectable metastatic liver cancer
- No invasion of major biliary structures
- No invasion of major vascular structures
- ASA score < 4
- WHO score 0-1
- Pre-operative chemotherapy is allowed
Exclusion Criteria
- Resectable liver metastases
- Life expectancy less than 3 months
- Patients with cardiac pacemaker, cerebral aneurysm clips, implanted electronic instruments or other metal materials
- Coagulopathy with platelet count less than 50000
- Active infectious disease
- Age below 18 years
- Pregnancy of breastfeeding
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description MWA Microwave ablation Patients undergoing MWA for hepatic metastases smaller than 3 cm, without underlying liver disease RFA Radiofrequency ablation Patients undergoing RFA for hepatic metastases smaller than 3 cm, without underlying liver disease
- Primary Outcome Measures
Name Time Method Variability of ablation diameters within the first 7 days and 3 months after surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University Hospital Gasthuisberg
🇧🇪Leuven, Vlaams-Brabant, Belgium